+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Idiopathic pulmonary fibrosis (IPF)

  • ID: 4846087
  • Report
  • May 2021
  • Region: Global
  • 41 Pages
  • Pharma Intelligence
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2019, there were 187,040 incident cases and 714,260 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts those numbers to increase to 209,960 incident cases and 798,760 prevalent cases by 2028.
  • Roche’s Esbriet and Boehringer Ingelheim's Ofev are the only approved drugs for IPF. These drugs are administered via the oral route.
  • The majority of industry-sponsored drugs in active clinical development for IPF are in Phase I. Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route.
  • High-impact upcoming events in the IPF space comprise topline Phase IIa trial results for PLN-74809, topline Phase IIb trial results for GB0139, topline Phase II trial results for BLD-0409, and topline Phase III trial results for pamrevlumab.
  • The overall likelihood of approval of a Phase I respiratory-other asset is 4.8%, and the average probability a drug advances from Phase III is 38.5%. Drugs, on average, take 12.8 years from Phase I to approval, compared to 9.8 years in the overall respiratory space.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
  • The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major European markets, while Israel has the top spot in Asia.
  • Clinical trial activity in the IPF space is dominated by completed trials. Roche has the highest number of completed clinical trials for IPF, with 20 trials.
  • Roche leads the industry sponsors with the highest overall number of clinical trials for IPF, closely followed by Boehringer Ingelheim.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis
TREATMENT
  • Pharmacologic treatment
  • Non-pharmacologic treatments
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • GLPG1690 for IPF (February 10, 2021)
  • GLPG1205 for IPF (December 1, 2020)
KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Lassen, Cedars-Sinai Investigate Role Of IL-11 In Lung Fibrosis
  • Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
  • Bridge, LegoChem Team To Speed Development Of Autotaxin Inhibitor
  • Galapagos Teams With Poland’s OncoArendi On IPF Candidate
  • Boehringer, Bridge IPF Deal Collapses On Toxicity Concerns
  • Reborn Redx Inks Global Licensing Deal With AstraZeneca
  • Galapagos Seeks IPF Discovery Leads From E-Therapeutics
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of IPF, 2019–28
Figure 2: Trends in prevalent cases of IPF, 2019–28
Figure 3: Overview of pipeline drugs for IPF in the US
Figure 4: Pipeline drugs for IPF, by company
Figure 5: Pipeline drugs for IPF, by drug type
Figure 6: Pipeline drugs for IPF, by classification
Figure 7: GLPG1205 for IPF (December 1, 2020): Phase II - PINTA
Figure 8: Key upcoming events in IPF
Figure 9: Probability of success in the respiratory-other pipeline
Figure 10: Clinical trials in IPF
Figure 11: Top 10 drugs for clinical trials in IPF
Figure 12: Top 10 companies for clinical trials in IPF
Figure 13: Trial locations in IPF
Figure 14: IPF trials status
Figure 15: IPF trials sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of IPF, 2019–28
Table 2: Prevalent cases of IPF, 2019–28
Table 3: Marketed drugs for IPF
Table 4: Pipeline drugs for IPF in the US
Table 5: GLPG1690 for IPF (February 10, 2021)
Table 6: GLPG1205 for IPF (December 1, 2020)
Table 7: Historical global sales, by drug ($m), 2016–20
Table 8: Forecasted global sales, by drug ($m), 2021–25
Note: Product cover images may vary from those shown
Adroll
adroll